# A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)

> **NCT07222189** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sanofi** · enrollment: 325 (estimated)

## Conditions studied

- Colitis Ulcerative
- Crohn's Disease

## Interventions

- **DRUG:** balinatunfib
- **DRUG:** balinatunfib-matching placebo

## Key facts

- **NCT ID:** NCT07222189
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-12
- **Primary completion:** 2030-05-10
- **Final completion:** 2030-05-10
- **Target enrollment:** 325 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222189, "A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07222189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*